Banyu Receives Japan Manufacturing Approval For Fosamax, Treatment Drug For Osteoporosis

Banyu Pharmaceutical Co., Ltd. obtained manufacturing approval for Fosamax Plus D - generic name: aledronate sodium - on July 26. Fosamax was first launched in Japan in 2001 and since has proven to be an effective drug for patients of post menopausal osteoporosis, indicating an efficiency reduction of cells that cause bone loss.


Fosamax is prescribed to 7 million patients worldwide. Taken once a daily, it can reduce the risk of vertebral compression fracture by 90% and femoral fracture by 51%. It also showed increased drug compliance by having it prescribed once a week.


By Aki Tsukioka, JCN Staff Writer


Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.


JCN


View drug information on Fosamax.